Un Audited Financial Result for 30th September, 2025

Emphasis of matterRelated-party transactionsNegative operating cash flowRevenue declinedAdverse audit opinionContingent liabilities increasedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹29.78

prior close

₹29.01

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+5.0% vs market

Pharmaceuticals peers, median of 157sector+0.0%+4.9% vs sector

On the reaction day the stock moved 5.0 pts more than Nifty Microcap 250 and 4.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.4

10m

-1.9

15m

-1.9

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9-0.1+5.0+0.0+4.9

Next day

+6.7+0.5+6.2-0.1+6.9

+11.6-0.3+11.9-0.9+12.5

+16.6-0.5+17.1-1.4+17.9

+22.4-0.8+23.2-1.6+24.0

+25.9-2.3+28.2-2.3+28.2

+34.8-2.8+37.6-3.1+37.9

15d

+39.0-4.9+43.8-3.6+42.5

+30.9-4.7+35.6-4.4+35.2

+46.4-7.7+54.1-5.7+52.1

+29.7-7.8+37.5-10.7+40.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bacil Pharma's Q2 FY26 results show the company had zero revenue from operations, with total revenue of just ₹5.49 lakhs (entirely from 'other income'), down sharply from ₹100.25 lakhs in Q1 FY26. Profit after tax collapsed to ₹1.38 lakhs versus ₹66.87 lakhs in the previous quarter. The statutory auditor flagged multiple serious concerns in an Emphasis of Matter, including: inability to verify the end-use of funds raised through preferential allotment, inability to confirm related party transactions, non-compliance with GST and TDS filing/deposit requirements, and reliance solely on management representations for investments and deposits. The auditor also invoked a 'Basis for Disclaimer of Opinion,' stating they could not obtain sufficient evidence. Operating cash flow turned sharply negative at ₹(142.62) lakhs versus ₹40.08 lakhs last year, and the cash balance fell from ₹285.73 lakhs to ₹159.38 lakhs.

Likely market impact

This is a deeply concerning filing — the company has no operating business revenue, the auditor has flagged significant compliance, documentation, and disclosure failures, and cash is being burned at a worrying rate. Shareholders should treat this as a high-risk situation warranting close scrutiny of management's use of funds and the company's ability to continue as a going concern.